Research reveals therapeutic potential of novel compound in inhibiting oncogene translation

FHS
July 24, 2023
9:09 am

Cutting-edge research at the Luxembourg Institute of Health reveals the ground-breaking therapeutic potential of the compound FL3 in inhibiting oncogene translation and rewiring cancer cell metabolism, opening up new therapeutic opportunities for leukemia patients.

Roche and Exelixis detail rare success for Cabometyx-Tecentriq combo in prostate cancer

The combination of Roche’s checkpoint inhibitor Tecentriq and Exelixis’ kinase inhibitor Cabometyx staved off disease progression of advanced prostate cancer for longer than a second

January 26, 2024

HeartMate 3 Safety Concerns; First Cath Lab Standards for Kids; Single-Shot PFA

Thoratec refuted most of the 4,500-plus reports that its HeartMate 3 left ventricular assist device may have caused or contributed to a patient’s death. (CBS

December 20, 2023

Meat and dairy industry lobbies to stifle competition from alternative meat products

The summertime barbecue – an American tradition synonymous with celebrating freedom – may be tainted by a decidedly unfree market.

August 18, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.